Stockreport

enGene Holdings: Key Catalysts Incoming For 2026 [Seeking Alpha]

enGene Holdings Inc.  (ENGN) 
PDF ENGN's lead candidate, detalimogene voraplasmid, demonstrated a 63% complete response rate at 3 months in NMIBC, with favorable tolerability and pivotal cohort enrollme [Read more]